Methodology of preclinical research of new anticancer agents;Méthodologie de la recherche préclinique de nouveaux agents anticancéreux

Bulletin du Cancer

Volumn 88, Issue 1, 2001, Pages 67-74

  Debussche, L ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CLINICAL RESEARCH; GENOME; METHODOLOGY; POLYMERASE CHAIN REACTION; REVIEW; THEORY; TUMOR DIAGNOSIS;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE LIBRARY; HUMANS; MODELS, ANIMAL; NEOPLASM PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NUCLEIC ACID HYBRIDIZATION; PHENOTYPE; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 0035104750     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. The war on cancer
2. The hallmarks of cancer
3. Genetic instabilities in human cancers
4. Aneuploidy and cancer
5. Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog
6. Series introduction: Taking aim at novel molecular targets in cancer therapy
7. Proteomics: Quantitative and physical mapping of cellular proteins
8. Can researchers find recipe for proteins and chips?
9. Antibody arrays for high-throughput screening of antibody-antigen interactions
10. Large-scale functional analysis using peptide or protein arrays
11. Cluster analysis and display of genome-wide expression patterns
12. Gene expression patterns and cancer
13. Gene expression profiling, genetic networks, and cellular states: An integrated concept for tumorigenesis and drug discovery
14. Isolation of genetic suppressor elements (GSEs) from random fragment cDNA libraries in retroviral vectors
15. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library
16. Integrating genetic approaches into the discovery of anricancer drugs
17. Tumor angiogenesis: Therapeutic implications
18. A cancer therapy resistant to resistance
19. Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance
20. Is angiogenesis inhibition the Holy Grail of cancer therapy?
21. Genes expressed in human tumor endothelium
22. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
23. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma
24. CTS1: A p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties
25. Onyx-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
26. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression
27. Use of minimally modified antisense oligonucleotides for specific inhibition of gene expression
28. Drug screening-beyond the bottleneck
29. How many leads from HTS?
30. High throughput screening for drug discovery: Continually transitioning into new technology
31. Discovering high-affinity ligands for proteins: SAR by NMR
32. Novel anti-cancer agents in development: Exciting prospects and new challenges
33. Lysophosphatidic acid receptors
34. PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer
35. Lysophospholipid growth factors in the initiation, progression, metastases, and management of ovarian cancer
36. Molecular targets in cancer drug discovery: Cell-based profiling
37. Development of a high volume screen to identify inhibitors of endothelial cell activation
38. Evaluation préclinique des médicaments anticancéreux: Un modèle reste un modèle!
39. What is the optimal rodent model for anti-tumor drug testing?
40. Orthotopic models are necessary to predict therapy of transplantable tumors in mice
41. Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer)
42. Quantitative angiogenesis assays: Progress and problems
43. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
44. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers
45. Molecular portraits of human breast tumours
46. Systematic variation in gene expression patterns in human cancer cell lines
47. A gene expression database for the molecular pharmacology of cancer
48. DNA arrays reveal cancer in its many forms
49. Activation of the PI3 K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors